Implication of the Autologous Immune System in BCR-ABL Transcript Variations in Chronic Myelogenous Leukemia Patients Treated with Imatinib. by Clapp, Geoffrey D et al.
Implication of the Autologous Immune System in
BCR-ABL Transcript Variations in Chronic
Myelogenous Leukemia Patients Treated with Imatinib.
Geoffrey D Clapp, Thomas Lepoutre, Raouf El Cheikh, Samuel Bernard,
Je´re´my Ruby, He´le`ne Labussie`re-Wallet, Franck E Nicolini, Doron Levy
To cite this version:
Geoffrey D Clapp, Thomas Lepoutre, Raouf El Cheikh, Samuel Bernard, Je´re´my Ruby, et
al.. Implication of the Autologous Immune System in BCR-ABL Transcript Variations in
Chronic Myelogenous Leukemia Patients Treated with Imatinib.. Cancer Research, American
Association for Cancer Research, 2015, 75 (19), pp.4053-62. <10.1158/0008-5472.CAN-15-
0611>. <hal-01251396>
HAL Id: hal-01251396
https://hal.inria.fr/hal-01251396
Submitted on 18 Jan 2017
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
BCR-ABL transcripts variations in chronic phase chronic myelogenous leukemia patients on 
imatinib: Possible role of the autologous immune system  
Authors: Geoffrey D. Clapp1, Thomas Lepoutre2, Raouf El Cheikh2, Samuel Bernard2, Jérémy Ruby3, 
Hélène Labussière-Wallet3,  Franck E. Nicolini3, Doron Levy4 
Affiliations: 
1 Department of Mathematics, University of Maryland, College Park, MD 20742, USA 
2 Inria, and Université de Lyon, Université Claude Bernard Lyon 1, CNRS UMR 5208, Institut 
Camille Jordan, 43 blvd. du 11 novembre 1918, F-69622 Villeurbanne cedex, France 
3 Centre Hospitalier Lyon, Sud, Pierre-Bénite France and CRCL, Centre Léon Bérard, Lyon, France, 
4 Department of Mathematics and Center for Scientific Computation and Mathematical Modeling 
(CSCAMM), University of Maryland, College Park, MD 20742, USA 
Corresponding author: Doron Levy  
Department of Mathematics and Center for Scientific Computation and Mathematical Modeling 
(CSCAMM), University of Maryland, College Park, MD 20742, USA 
Email: dlevy@math.umd.edu 
Phone: (301)405-5140 
Fax: (301)-314-6674 
Key words: CML, BCR-ABL, TKI, immune system 
Short title: Autologous immune system and chronic phase CML  
Abstract 
Tyrosine kinase inhibitors (TKIs), such as imatinib (IM), have significantly improved treatment 
of chronic myelogenous leukemia (CML). However, the majority of patients are not cured for 
undetermined reasons. A more complete understanding of their mechanisms of action would help 
to identify limitations of TKI therapy alone and could inform the use of combination therapies 
aimed at controlling or definitively eradicating the residual leukemic population. Based on our 
patients' data, we found that many patients who otherwise responded well to IM therapy still 
showed variations in their BCR-ABL transcripts. To investigate this phenomenon, we applied a 
mathematical model that integrates CML and an autologous immune response to the patients' 
data. We define an immune window, or a range of leukemic loads for which the autologous 
immune system induces an improved response. Our modeling results suggest that, at diagnosis, a 
patient's leukemic load is able to partially or fully suppress the autologous immune response 
developed in a majority of patients, towards the CML clone(s). IM therapy drives the leukemic 
population into the "immune window", allowing the patient's autologous immune cells to expand 
and eventually mount an efficient recognition of the residual leukemic burden. This response 
drives the leukemic load below this immune window, allowing the leukemic population to 
partially recover until another weaker immune response is initiated. Thus, the autologous 
immune response may explain the oscillations in the BCR-ABL transcripts regularly observed in 
patients on IM. 
Major Findings:  
Based on patient data and our model, we hypothesize that the autologous immune system plays a 
significant role in the dynamics of CML during IM therapy. Moreover, variations in the BCR-
ABL transcripts during IM therapy may represent a signature of the patient's individual 
autologous immune response. Immunotherapy may complement IM and other TKIs by helping 
to maintain a patient's autologous immune response when the leukemia stimulus alone is 
insufficient. Our mathematical model is a potentially valuable tool in studying and designing 
patient-specific schedules for these combination therapies. 
 
  
 Introduction 
 Chronic myeloid leukemia (CML) is a myeloproliferative disorder caused by the BCR-
ABL fusion oncogene, which encodes for a constitutively active tyrosine kinase. Tyrosine kinase 
inhibitors (TKI), such as imatinib (IM), are targeted therapies that have revolutionized the 
treatment of CML, producing durable remissions in many patients and resulting in substantially 
improved long-term survival rates [1, 2]. Despite their success, their global therapeutic effect 
remains incompletely understood.  Moreover, it is unclear whether TKIs alone are capable of 
eliminating the entire leukemic burden, as many patients in long-term remissions continue to 
harbor small residual leukemic loads even after many years of therapy [3]. A better 
understanding of TKIs would allow us to improve the way that these drugs are administered and 
also to identify their limitations. If TKIs prove to be incapable of curing most patients, then 
understanding the drugs' mechanisms of action may inform our use of combination therapies.  
 There is compelling evidence that a patient's autologous immune response plays a 
significant role in the dynamics of CML. It is known that immune cells are capable of detecting 
and eliminating cancer cells [4]. Immunotherapy is a major goal of immunology and cancer 
research because of the ability of the immune system to target and eliminate abnormal cells 
while leaving healthy cells intact. In the allogeneic setting, the immune system has demonstrated 
its power in the elimination of residual CML disease [5]. Several combination therapies 
involving interferon-alfa (IFN-α) are currently being investigated [6, 7, 8], in part, because of 
this drug's effects on the autologous immune system [8], which participates in the control of the 
disease. Additionally, IFN-α may drive quiescent leukemic stem cells into the cell cycle [9, 10], 
where they become exposed to the effects of TKIs.  
 In the Stop Imatinib (STIM) [11] and TWISTER [3] trials, patients who responded well 
to IM were taken off therapy in order to determine whether treatment-free remission (TFR) could 
be achieved. They found that approximately 40% of patients remained in TFR for at least two 
years after stopping treatment. Moreover, although not statistically significant, the TFR rate was 
higher in patients that had received interferon prior to IM [11]. In many of these patients, BCR-
ABL DNA and mRNA were still detectable [3]. Moreover, in [12], patients still harbored BCR-
ABL+ leukemic stem cells, despite having remained in TFR for up to eight years. In these cases, 
since treatment did not completely eradicate the disease, some other mechanisms, such as the 
autologous immune system, must be preventing this residual cancer population from expanding. 
Motivated by these results, we constructed a mathematical model integrating CML and the 
autologous immune response.  
  
Materials and Methods 
 A group of 104 patients with CML was monitored during IM therapy in the Centre 
Hospitalier Lyon Sud. These patients were all treated with first-line IM 400 mg daily. Patients' 
BCR-ABL ratios were measured in the same laboratory, with the same technique at diagnosis, at 
months 3, 6, 9, and 12 of therapy, and every 6 months thereafter. Overall, the patients had an 
average follow-up time of 62.76 months (range: 2.96 - 148.70), with an average of 12.69 
measurements taken (range: 2 - 26). We excluded patients who changed TKIs for safety reasons 
(n = 33) and patients whose disease progressed (n = 14), as we focused exclusively in this study 
on patients obtaining a residual disease on IM. Thus, a population of 65 patients who responded 
well to IM remained for analysis. 
 BCR-ABL ratios were serially measured by quantitative RT-PCR in the peripheral blood 
of patients in a single laboratory according to the European standards of European Leukemia Net 
[13, 14]. Each sampling was run in parallel to the previous (frozen) sample from each patient in 
order to exclude technical problems, at each time point (except diagnosis) for all patients. 
 Our mathematical model divides leukemic cells into quiescent stem cells (y0), cycling 
stem cells (y1), progenitors (y2), and mature cells (y3). We also represent a single autologous 
immune cell population (z). For simplicity, we do not distinguish further between immune 
subpopulations. Leukemia cells stimulate immune cells to proliferate at a maximum rate α, while 
immune cells kill leukemia cells at a maximum rate μ. We incorporate immunosuppression by 
inhibiting the proliferation of the immune cells as well as their action on leukemic cells. Our 
model is summarized in Figure 1. A more thorough description of the model is provided in the 
"Quick Guide to Equations and Assumptions." 
 The BCR-ABL ratio is a blood measurement that quantifies the amount of BCR-ABL 
transcript relative to a control transcript, BCR or ABL (here, ABL). Each leukemic cell 
possesses the BCR-ABL gene and the normal allele of ABL gene, while healthy cells (x) possess 
two alleles of the ABL gene. Therefore, BCR-ABL transcripts are proportional to y3 (the 
immature leukemia cell populations are much smaller than the mature population and can be 
neglected), while control transcripts are approximately proportional to 2x + y3. For simplicity, the 
number of healthy cells (x) is assumed to be constant and is estimated based on the patient's 
initial BCR-ABL ratio at diagnosis. For all later measurements, the BCR-ABL ratio is 
approximated by 
ratio ≈ 100β
y3
2x + y3
 
The multiplication factor β accounts for differences in mRNA expression between BCR-ABL 
and the control gene. We multiply by 100, in order to convert the ratio into a percentage when β 
= 1 and a value between 0 and 100β otherwise.  
  
Quick Guide to Equations and Assumptions 
 We develop an ODE model of CML and the immune system, to study the dynamics of 
IM therapy. Specifically, we seek to understand patients whose BCR-ABL ratios vary non-
monotonically during therapy.  
 Let y0, y1, and y2, and y3 represent the concentrations of quiescent leukemic stem cells, 
cycling leukemic stem cells, progenitor leukemic cells, and mature leukemic cells. Let z denote 
the concentration of immune cells. We consider the following system of ODEs.  
 ẏ0 = b1y1 − a0y0 −
μy0z
1 +  εy3
2 
(1) 
 ẏ1 = a0y0 − b1y1 +  ry1 (1 −
y1
K
) − d1y1 −
μy1z
1 +  εy3
2 
(2) 
 ẏ2 = a1y1 − d2y2 −
μy2z
1 +  εy3
2 
(3) 
 ẏ3 = a2y2 − d3y3 −
μy3z
1 +  εy3
2 
(4) 
 ż = sz − dzz +
αy3z
1 +  εy3
2 
(5) 
 
 In Equations (1) and (2), a0 and b1 represent the transition rates of leukemic stem cells 
from quiescence to cycling and cycling to quiescence, respectively. We assume logistic growth 
of cycling stem cells, with growth rate r and carrying capacity K. Cycling stem cells die naturally 
at a rate d1. In Equation (3), the first term represents the differentiation of stem cells into 
progenitors. The coefficient a1 is the product of the differentiation rate and the amplification 
factor upon differentiation due to cell proliferation. Progenitors die naturally at a rate d2. 
Equation (4) is similar to (3), with differentiation rate a2 and death rate d3. The last terms in 
Equations (1)-(4) represent the death of leukemic cells caused by an immune response. The mass 
action term μyiz represents the killing of leukemic cells by the immune system, where μ is the 
maximal rate (per immune cell) at which an immune cell will engage and kill a leukemic cell. 
Equation (5) represents the concentration of autologous immune cells. The first term, sz, is a 
constant source term. Immune cells die at a rate dz. The mass action term αy3z represents the 
expansion (proliferation) of the immune cell pool in response to its leukemia stimulus, which 
occurs with maximal rate per leukemic cell α. We include only the contributions of the mature 
leukemic cells y3 to immune stimulation since they are a much larger population than the 
immature leukemic cells (ytotal ≈ y3). 
 Our model is based on the assumption that immunosuppression acts in two ways. First, 
mature leukemic cells inhibit the expansion of immune cells. In Equation 5, the immune cell 
expansion term αy3z is divided by 1 + εy32, where the constant ε determines the strength of the 
immunosuppression. Second, mature leukemic cells are assumed to decrease the killing capacity 
μ of activated immune cells, also by a factor of 1 + εy32. This effect is represented in the last 
terms in Equations (1)-(4). This approach is similar to the one used in [15]. By implementing 
immunosuppression in this way, we encode an autologous immune response that is effective only 
with intermediate levels of leukemic cells. When the leukemic load is small, only a small number 
of immune cells is stimulated to respond. On the other hand, although large leukemic loads 
provide a stronger stimulus, the leukemic cells are able to suppress the efficacy of the immune 
system. Thus, the immune response will be negligible when the leukemic load is either very 
small, at levels undetectable by the immune system, or very large, at levels that overwhelm and 
suppress the immune system. A strong immune response can occur only when the leukemic load 
y3 is at an intermediate level, within a range [ymin, ymax] that we call the immune window. In our 
model, we define the immune window as the range of y3 for which the rate of immune 
stimulation (
αy3
1+ εy3
2) exceeds the death rate (dz). IM therapy may be used to drive the leukemic 
load into this immune window, allowing the autologous immune system to assist the drug in the 
elimination of the leukemic cells. 
 IM is known to block the kinase activity of the BCR-ABL protein, which results in a 
significant decrease in the proliferation rates of the BCR-ABL+ leukemic cells [1, 16] and 
apoptotic death [17]. However, we focus here on the effects of IM on proliferation and leave 
incorporation of other mechanisms to a future work. We implement IM therapy in the model by 
decreasing the differentiation/amplification rates a1 and a2 to lower values a1' = a1 / inh1 and a2' = 
a2 / inh2. It is unknown how IM affect LSCs and whether quiescent LSCs are affected at all, so 
we assume no direct effect of IM on these populations. However, our model provides a 
framework for testing various mechanisms of actions of IM, which we leave for a future work. 
 It is also unclear whether IM is capable of completely eliminating the leukemic cell 
burden, or whether small residual populations will persist indefinitely. In our model, a 
leukemic load of zero can only be approached asymptotically, so we define cure as a cancer 
stem cell concentration less than 1.67(10)-4 cells/mL, which corresponds to less than one 
leukemic stem cell. We stop all simulations of the model whenever this is achieved.
Results 
 Many patients who otherwise respond well to therapy exhibit oscillations in their BCR-
ABL ratios. Of the 104 patients in our data set, only 15 showed monotonically decreasing BCR-
ABL ratios throughout therapy. Each of the remaining 89 patients showed increases in BCR-
ABL ratios in, on average, 28.82% of their measurements. Two representative patients are shown 
in Figure 2. These fluctuations occurred in many patients who responded well to IM therapy and 
did not have any adverse events. This lack of monotonicity in patients who responded well to 
therapy motivated this study. 
 We applied our mathematical model, which is summarized in Figure 1, to the patient data 
in order to study these oscillations. As previously mentioned, our model represents leukemic 
cells of varying maturity and a single immune cell population. We applied Latin hypercube 
sampling in order to determine the effect of the drug (a1' and a2') and the immune parameters (μ, 
dz, α, and ε). The parameters dz, α, and ε determine the patient's immune window [ymin, ymax], or 
the range of leukemia loads that will stimulate a strong immune response. We define [ymin, ymax] 
by the range of y3 for which the level of immune stimulation exceeds the death rate. For each 
patient, we selected the parameter set that minimizes the squared log-distance between the 
patient data and the results of the model simulation (sampled at the same time as the data). All 
other parameters were held constant across all patients; their values can be found in Table S1 of 
the Supplementary Material. The patient-specific parameter values are summarized in Table 1. 
Figures 3 and 4 show representative fits of our model to patient data. (The patient-specific 
parameters producing these fits are provided in Table S2 of the Supplementary Material.) 
Keeping in mind that these fits are plotted on a logarithmic scale, we see that our model is able to 
reproduce many patients' dynamics during therapy.  
 The patient data and modeling results suggest that patients who respond well to IM 
therapy go through three to four phases of tumor reduction. During the first few months, there is 
a rapid exponential decline in BCR-ABL ratio. In our model, this effect is due primarily to the 
action of the drug on the mature leukemic population. The immune response is negligible at this 
stage because the large leukemic load suppresses the immune system. Beginning around month 
six, there is a second, slower exponential decline in BCR-ABL ratio. In some patients, the 
second phase is a plateau in BCR-ABL ratio rather than a decline (see Figures 3d). The location 
of this plateau is determined primarily by the direct effects of IM on the leukemic cell population 
(parameters inh1 and inh2). This biphasic exponential decline has been previously observed in 
[18] and [19]. A few patients show a triphasic exponential decline (Figures 4b-d), which was 
discussed in [20].  
 The duration of the biphasic or triphasic decline can vary significantly between patients, 
from the first two years (Figures 3a, 3c, 3d, 4f) to several years of therapy (Figures 4b-d). After 
this period of monotonic decline, many patients' leukemic loads begin to vary non-
monotonically. In our model, these variations are explained by an autologous immune response 
that occurs after therapy drives the leukemic population into the immune window. When the 
leukemic population enters the immune window, the immune cells continue to expand until they 
can mount a first attack on the leukemic cells. This first attack results in a sharp decline in the 
leukemic population, as in Figures 3f, 4b, and 4d-f, and often produces the minimum leukemic 
burden achieved during therapy. If this first response is sufficiently strong, it may drive the 
leukemic stem cell population to less than one cell, which we interpret as cure in our model. 
Otherwise, the immune cells contract once the leukemic population falls below the immune 
window, and the leukemic population is able to partially recover. Several oscillations between 
the leukemic and immune cells follow, with their amplitudes decreasing over time as the 
populations approach an equilibrium, as seen in Figure 5.  
 The patient-specific parameters are summarized in Table 1. Of the six parameters varied, 
the fits seem to be most sensitive to inh1 and inh2, followed by ymin and ymax. The parameters dz 
and μ seem to be less important. This is not surprising, as inh1 and inh2 determine the effect of 
the drug, and ymin and ymax determine at what point the autologous immune response becomes 
significant. Scatter plots depicting parameter sensitivities for a representative patient are shown 
in Figure 6. 
 The parameter values in Table 1 suggest that IM alone results in a 3.5-log decrease in the 
total leukemia load, on average (STD: 0.786, max: 5.158, min: 2.426). This effect is divided into 
a 2.5-log decrease in the proliferation of mature cells and a 1-log decrease in the proliferation of 
progenitors. Each patient's immune window covers approximately one order of magnitude of 
leukemic populations, generally falling between 102.5 cells/mL and 106 cells/mL. We assume an 
initial mature leukemic population of 1.5(10)8 cells/mL. Thus, IM must decrease the leukemia 
load by several orders of magnitude before the leukemia enters the immune window and an 
immune response is initiated. After the leukemic population enters this window, the leukemia 
and immune populations oscillate, with the amplitude of oscillations decreasing over time. 
 
  
Discussion 
 Despite the success of IM and other TKI therapies, many questions about the underlying 
mechanisms of action remain. Mathematical modeling is a complementary tool to clinical and 
experimental data that can help us understand these mechanisms. Several mathematical modeling 
groups have already studied various aspects of CML [15, 18, 19, 21, 22, 23, 24]. We briefly 
review some of these contributions but note that a more thorough review can be found in [25].   
 Michor et al. [18] constructed an ordinary differential equations (ODE) model of CML 
that divides leukemic cells into stem cells, progenitors, differentiated cells, and terminally 
differentiated cells. Upon analyzing patients' initial responses to IM therapy, they found that IM 
often lead to biphasic exponential declines in the leukemic cell populations. Their modeling 
results suggested that the first, steeper decline represents the action of IM on the differentiated 
leukemic cell population, while the second, slower decline represents an effect on the leukemic 
progenitors. They later hypothesized that long-term therapy leads to a triphasic exponential 
decline, where the third decline may represent an effect on immature leukemic cells and possibly 
leukemic stem cells [20].  
 On the other hand, Roeder et al. [19] developed an agent-based model of CML that 
divides leukemic stem cells into cycling and quiescent compartments. In their model, IM results 
in the degradation and inhibition of cycling leukemic stem cells while having no direct effect on 
quiescent leukemic stem cells. They interpreted the biphasic exponential decline as an initial 
degradation effect, followed by a change in the regulatory response of leukemic stem cells which 
produces the second decline. A similar interpretation to the biphasic decline is proposed in [22]. 
 Although these modeling frameworks are capable of reproducing the dynamics of some 
patients during therapy, both are limited to those who show a monotonic decline in their 
leukemic burdens. Neither model includes a mechanism that would allow patients to show 
oscillations in leukemia load. However, in our data, we found that many patients who respond 
well to IM and achieve long-term remissions exhibit increases in leukemic burden. The fact that 
the Michor and Roeder models are unable to reproduce such oscillations suggests that there may 
be (an) additional mechanism(s) that contribute(s) to patients' dynamics during therapy. 
 Motivated by this, we developed a mathematical model that integrates CML and an 
autologous immune response. As previously mentioned, there is strong evidence that the immune 
system plays a role in the dynamics of CML [3, 4, 8, 26, 27]. In our modeling framework, we 
defined an immune window, or a range of leukemic loads that will provoke a strong autologous 
immune response. At diagnosis, the leukemic load is above this window, and the large leukemic 
population is able to partially or fully suppress the autologous immune system's response to 
CML. IM therapy generally reduces a patient's leukemic load by several orders of magnitude, 
representing a significant reduction in immunosuppression. We hypothesize that IM may drive 
the leukemic population into the immune window, allowing a patient's autologous immune 
system to mount a response to CML.  
 In our model, oscillations in leukemic load occur after the leukemia enters the immune 
window. Once the autologous immune cells have expanded sufficiently, they attack the residual 
leukemic population. This first attack by the autologous immune system results in the minimum 
detectable leukemic load achieved during IM therapy. However, because the leukemia is driven 
below the immune window, the patient's immune cells begin to contract. If the leukemia is not 
eradicated, it is able to rebound, until it reenters the immune window, thus stimulating another 
weaker immune response. The immune and leukemic cell populations continue to oscillate in this 
way, with the amplitude of these oscillations decreasing over time. Eventually, the oscillations 
dampen, and an equilibrium is achieved between the leukemic and autologous immune cells.
 Our modeling results suggest that oscillations in BCR-ABL ratio during therapy may be 
partially explained by the patient's autologous immune response to the residual CML population.  
Moreover, the oscillations may be a signature of the autologous immune response, that can be 
used to characterize a patient's individual immune system. Each patient's immune profile is 
different, as demonstrated by differences in the immune windows and in the timing and 
magnitude of the autologous immune response to CML. Our modeling framework provides a 
potential tool to help quantify these differences, which may play a significant role in designing 
personalized therapies or combination therapies aimed at eradicating the residual CML burden. 
  
Conclusion 
 The potentially significant role of the immune system in the dynamics of IM therapy 
suggests that immunotherapy may help to eliminate the residual leukemic burden. In our 
simulations, when IM therapy drives the leukemia into the immune window, an initially strong 
immune response occurs that weakens over time. Eventually, the immune cell population 
contracts, allowing the leukemia to partially recover. A combination of IM and immunotherapy 
may help to maintain a strong immune response, to prevent such a recovery in the leukemic 
population. As suggested in [15], carefully-timed vaccines may stimulate the patient's immune 
system when the residual CML burden is no longer sufficient. A sustained immune response may 
result in a further decrease of the leukemic population and may even drive the leukemia to 
extinction. An optimal vaccine schedule would depend heavily on each patient's immune profile, 
and our model offers a tool for characterizing this. 
 Although we focus on the autologous immune response as a possible explanation of the 
oscillations that occur during IM therapy, many other factors may contribute to this behavior. 
The microenvironment of the leukemic cells is known to have a strong influence on both healthy 
and leukemic cells [28, 29], but is not included in our model. Additionally, we do not account for 
patients who do not properly or regularly take their drugs, which is known to be an important 
factor [30]. Moreover, for simplicity, we do not distinguish between various subtypes of immune 
cells, each of which may interact and play different roles in CML. Our model can be expanded in 
order to achieve a more accurate representation of the autologous immune response to CML. We 
leave this for a future work.  
 Still, the oscillations in patients' leukemic loads suggest an additional mechanism during 
therapy that has not previously been included in mathematical models. Our modeling results 
support the hypothesis that the autologous immune system contributes to the dynamics of IM 
therapy. If this is the case, our model may serve as a valuable tool for characterizing a patient's 
immune response to CML. This immune profile may then help in designing personalized 
combination therapies in order to eliminate or control the residual leukemic burden. 
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 Figure 1. Mathematical model including the intervention of the autologous immune system. 
In our model of CML and the immune response, we divide leukemic cells into quiescent stem cells (y0), 
cycling stem cells (y1), and progenitors (y2), and mature cells (y3). Stem cells transition between 
quiescence and cycling, and some cycling stem cells differentiate into progenitors cells, which can further 
differentiate into mature cells. Leukemic cells can die naturally at rates di or as a result of an interaction 
with immune cells (z). Immune cells are supposed in this disease to be supplied at a constant rate sz and to 
die at a rate dz. They can also be stimulated by leukemic cells to divide to produce more immune cells. 
Large leukemic populations are able to suppress the autologous immune system, by limiting immune cell 
expansion and limiting immune effector cells' ability to kill cancer cells.  
  
  
 
Figure 2. Oscillations of the BCR-ABL ratio in two representative patients.  
During TKI therapy, a patient's progress is monitored by measuring their BCR-ABL ratio, which is a ratio 
of BCR-ABL mRNA expression to the expression of a control gene, in this case ABL. Both patients 
shown above were treated with standard IM 400 mg daily. During treatment, both patients show multiple 
increases in BCR-ABL ratio without overt relapse. Here, dots represent clinical data, and the dashed line 
approximates the detection threshold, or the lowest detectable leukemia level. Dots along this line mark 
indicate times measurements of zero, meaning the leukemia was undetectable within the limits of the 
assay. These figures correspond to patients 4 and 12 in Table S2 of the Supplementary Material. 
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Figure 3. Fits of our mathematical model to six representative patients. 
The base-10 log of the BCR-ABL ratio is plotted against time, in months. The dots represent patient data, 
and the solid lines represent our simulations. Dashed lines show the BCR-ABL ratios that correspond to 
the ends of immune window, ymin and ymax. These figures correspond to patients 1-6 in Table S2 of the 
Supplementary Material.  
(a) (b)  
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Figure 4. Fits of our model to six additional patients. 
The base-10 log of the BCR-ABL ratio is plotted against time, in months. As in Figure 3, the dots 
represent patient data, and the solid lines represent our simulations. Dashed lines show the BCR-ABL 
ratios that correspond to the ends of immune window, ymin and ymax. Dotted lines approximate the 
minimum leukemic level that is detectable by RQ-PCR. Dots along this line represent zero measurements, 
meaning CML cells were not detected. These figures correspond to patients 7-12 in Table S2 of the 
Supplementary Material. 
  
 Figure 5. Model simulation for a single representative patient. 
 The base-10 log of the leukemia and immune cell populations, in cells/mL, are plotted as a function of 
time, in months. The thick solid line represents the total leukemic population (y0 + y1 + y2 +  y3), and the 
thick dashed line represents the immune cell population (z). The thin solid lines show the immune 
window [ymin , ymax] = [104.58 ,105.44] cells/mL. For the first twenty months, the patient's leukemia load 
decreases monotonically, while the immune cells begin to expand. The leukemic population enters the 
immune window at around month 7. The immune cells mount an attack starting around month 18. This 
first attack results in the minimum leukemia load achieved during therapy, at around 104 cells/mL. The 
immune cells drive the leukemia load below the immune window, allowing the leukemic population to 
partially recover. The two populations oscillate with decreasing amplitudes as they approach their 
equilibrium concentrations of (y, z) = (104.61, 105.85) cells/mL. This simulation corresponds to the plot in 
Figure 3d (patient 4 in Table S2). 
  
(a) (b)  
(c)  
Figure 6. Quality of the fit as a function of a pair of parameters, for a single representative patient. 
This is the same patient whose simulation is shown in Figures 3d and 5 (patient 4 in Table S2). Red dots 
indicate worse fits, and dark blue dots indicate better fits. Here, we only show simulations that resulted in 
a total cost of less than 10, where cost is the squared log-distance between the patient data and model 
simulation. (a) log(inh2) vs.  log(inh1). For this patient inhibition values satisfying log(inh1 inh2) in [2, 4] 
were tested. These two parameters are strongly related to the quality of the fit. (b) log(μ) vs. dz. These two 
parameters seem to be the least important, as it is difficult to see any correlation between the fit and either 
of these parameters. (c) ymax vs. ymin. There is a definite relationship between the fit and these two 
variables. The worse fits tend to be in the upper left corner, while the better fits tend to be in the lower 
right corner. The parameters ymax and ymin determine the immune window and therefore affect the timing 
and magnitude of the autologous immune response.  
  
Parameter log(inh1) log(inh2) dT log(μ) log(ymin) log(ymax) log(ymax / ymin)  
Mean 1.132 2.487 0.099 -7.047 3.970 5.024 1.053 
STD 0.830 0.754 0.097 0.636 0.888 0.804 0.499 
Max 2.772 3.880 0.371 -5.896 5.483 6.024 2.006 
Min 0.024 1.073 0.005 -7.954 2.548 3.226 0.197 
 
 
Table 1. Summary of parameter values used in our model simulations. 
Of the 65 patients IM patients who do not relapse, develop drug resistance, or progress, 22 change their 
IM dose during therapy. An additional 6 patients have non-IS measurements, and 11 patients have five or 
fewer measurements. We focus on the remaining 25 patients and present the mean, standard deviation, 
maximum, and minimum parameter values. 
   
Supplementary Material  
Parameter Description Value Source 
y0(0) Initial leukemic quiescent stem cell 
concentration 
37.5000 Estimated based on [18] 
y1(0) Initial leukemic cycling stem cell 
concentration 
4.1667 Estimated based on [18] 
y2(0) Initial leukemic progenitor 
concentration 
1.6667(10)4 [18] 
y3(0) Initial leukemic mature cell 
concentration 
1.5(10)8 [31] 
z(0) Initial autologous immune cell 
concentration 
120 Estimated based on [31] 
a0 Stem cell transition rate to cycling 0.0027 Estimated 
b1 Stem cell transition rate to quiescence 0.0247 Estimated 
r Cycling stem cell growth rate 0.08 Estimated based on [15] 
K Cycling stem cell carrying capacity 4.2872 Estimated 
a1 Differentiation rate and expansion 
factor for progenitors 
24.0005 Estimated  
a2 Differentiation rate and expansion 
factor for mature cells 
899.9820 Estimated  
d1 Cycling stem cell death rate 0.00225 [15] 
d2 Progenitor cell death rate 0.006 [15] 
d3 Mature cell death rate 0.0375 [15] 
sz Source term for autologous immune 
cells 
120 * dz Estimated 
β Adjustment factor for BCR-ABL 
ratio 
3 Estimated based on patient 
data 
 
Table S1. Universal parameter estimates. This table provides the values of the universal 
parameters. Cell concentrations are in cells/mL. The initial values y0(0) + y1(0) and y2(0) are 
chosen based on the initial number of leukemic stem (2.5(10)5 cells) and precursor cells (1(10)8 
cells) in [18], converted to cells/mL by assuming a blood volume of 6 L. The value y3(0) is 
estimated in [31]. The value z(0) is also based on [31], assuming a concentration of 6(10)5 
cells/mL, of which about 1/5000 is specific to leukemia. Quiescent stem cells enter the cell cycle 
infrequently [32], so we set a0 equal to 1/365 days
-1. The parameter b1 is set to 9a0 so that most 
stem cells in our model are quiescent, which is in agreement with [33]. Thus, the two stem cell 
populations will approximately have a 1:9 ratio, so we set y0(0) = 0.1 (y0(0) + y1(0)) and y1(0) = 
0.1 (y0(0) + y1(0)). The death rates d1, d2, and d3 are set to those in [15]. The stem cell growth 
rate is also based on the value in [15]. We increase the original value (r = 0.008) by a factor of 10 
to account for the fact that only 10% of the stem cells in our model contribute to growth, while 
all stem cells contribute to growth in [15]. The parameters K, a1, and a2 are selected so that the 
initial conditions represent a steady state when the immune response is removed from the model. 
(That is, y1(0) = K(r - d1)/r, y0(0) = b1y1(0)/a0, y2(0) = a1y1(0)/d2, and y3(0) = a2y2(0)/d3.) We 
assume that z(0) = sz / dz, so the value of dz determines sz. Lastly, the adjustment factor β is 
selected based on the maximum BCR-ABL ratio (269) in our data set.   
Patient inh1 inh2 dT μ ymin ymax 
1 9.944 131.016 0,187 4.021(10)-8 6.001(10)4 1.754(10)5 
2 33.268 148.517 0.131 1.515(10)-8 1.443(10)4 4.521(10)4 
3 4.612 92.3215 0.031 9.964(10)-7 4.994(10)4 5.598(10)5 
4 1.456 545.150 0.099 1.504(10)-8 3.765(10)4 2.759(10)5 
5 1.872 1700.274 0.128 3.082(10)-7 2.482(10)4 6.513(10)4 
6 9.652 43.752 0.238 1.350(10)-7 1.050(10)5 8.637(10)5 
7 5.771 155.963 0.019 4.057(10)-8 4.846(10)4 3.695(10)5 
8 591.591 14.568 0.040 2.371(10)-7 3.132(10)3 2.228(10)4 
9 486.315 226.000 0.075 2.879(10)-8 3.536(10)2 1.684(10)3 
10 50.988 79.645 0.005 1.271(10)-6 1.182(10)3 5.482(10)4 
11 30.208 359.979 0.371 2.263(10)-7 4.959(10)3 1.353(10)4 
12 1.5201 265.6435 0.015 2.748(10)-8 2.031(10)4 9.352(10)5 
 
Table S2. Patient-specific parameter estimates.  
Parameter values for patients 1-6 were used to produce Figure 3, while parameter values for 
patients 7-12 were used to produce Figure 4. Here, ymin and ymax can be used to obtain immune 
parameters ε = 1 / (ymin ymax) and α = (ymin ymax) εdz. 
 
